Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 24.
doi: 10.1007/s12035-024-04543-4. Online ahead of print.

Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis

Zaida L Almeida  1 , Daniela C Vaz  2   3   4   5 , Rui M M Brito  6
Affiliations
Review

Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer's Pathogenesis

Zaida L Almeida et al. Mol Neurobiol. .

Abstract

Alzheimer's disease (AD) is the most common form of dementia around the world (~ 65%). Here, we portray the neuropathology of AD, biomarkers, and classification of amyloid plaques (diffuse, non-cored, dense core, compact). Tau pathology and its involvement with Aβ plaques and cell death are discussed. Amyloid cascade hypotheses, aggregation mechanisms, and molecular species formed in vitro and in vivo (on- and off-pathways) are described. Aβ42/Aβ40 monomers, dimers, trimers, Aβ-derived diffusible ligands, globulomers, dodecamers, amylospheroids, amorphous aggregates, protofibrils, fibrils, and plaques are characterized (structure, size, morphology, solubility, toxicity, mechanistic steps). An update on AD-approved drugs by regulatory agencies, along with new Aβ-based therapies, is presented. Beyond prescribing Aβ plaque disruptors, cholinergic agonists, or NMDA receptor antagonists, other therapeutic strategies (RNAi, glutaminyl cyclase inhibitors, monoclonal antibodies, secretase modulators, Aβ aggregation inhibitors, and anti-amyloid vaccines) are already under clinical trials. New drug discovery approaches based on "designed multiple ligands", "hybrid molecules", or "multitarget-directed ligands" are also being put forward and may contribute to tackling this highly debilitating and fatal form of human dementia.

Keywords: Alzheimer’s disease (AD); Amyloid plaques; Amyloid-beta (Aβ) peptide; Aβ-based therapies; Protein aggregation; Tau protein.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Sehar U, Rawat P, Reddy AP et al (2022) Amyloid beta in aging and Alzheimer’s disease. Int J Mol Sci 23:12924. https://doi.org/10.3390/IJMS232112924 - DOI - PubMed - PMC
    1. Alberdi A, Aztiria A, Basarab A (2016) On the early diagnosis of Alzheimer’s disease from multimodal signals: a survey. Artif Intell Med 71:1–29. https://doi.org/10.1016/J.ARTMED.2016.06.003 - DOI - PubMed
    1. Duncan BB, Schmidt MI, Collaborators G 2019 (2022) Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study. BMJ 376:e068208. https://doi.org/10.1136/bmj-2021-068208
    1. Javaid SF, Giebel C, Khan MA, Hashim MJ (2021) Epidemiology of Alzheimer’s disease and other dementias: rising global burden and forecasted trends. F1000Research 10:425. https://doi.org/10.12688/f1000research.50786.1 - DOI
    1. (2022) 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 18(4):700–789. https://doi.org/10.1002/ALZ.12638

LinkOut - more resources